BKLYN CBD GUMMIES - CRANBERRY, BLUEBERRY or
BKLYN CBD GUMMIES - CRANBERRY, BLUEBERRY or
Made in small batches by hand with ingredients you know and can pronounce. Our all natural cranberries gummies are infused with the finest organic CBD, creating a delicious blend of cranberries and CBD. Maintain your inner cool with these gummies*. Each gummy contains 20mg of CBD (for a total of 180mg of CBD per mason jar).
9 gummies per jar
20mg of CBD per gummy
Non-psychoactive CBD made from organic U.S. hemp
Ingredients you know and can pronounce
No added sugar, preservatives or coloring
Need to know: If you don't feel anything at first, be patient. Just like when you start taking a new supplement or regimen, it takes time to feel the full effects. Stay consistent. The results are cumulative and oftentimes subtle at first.
Ingredients: Natural infused Maine cranberry, made with pure non-gmo Maine cranberry extract, or Natural infused Maine blueberry or made with pure non-gmo Maine blueberry extract or Natural infused Maine apples, made with pure non-gmo Maine apple extract plus apple cider syrup, gelatin (non vegan), citric acid.
Store in a dry, cool place
If your employment requires a drug test, please talk to your employer or physician first. Contains less than 0.3% THC.
Keep out of reach of children. Consult your doctor before taking if you are pregnant or nursing, have a medical condition, or take pharmaceutical drugs.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Why CBD?
CBD THERAPEUTIC BENEFITS
The World Health Organization published a report on CBD in November of 2017. Below is an overview in which CBD may have therapeutic benefits.
Disease
Effects
Alzheimer's disease
Antinflammatory, antioxidant, antiapoptotic in in vitro and in vivo models
of Aβ-evoked neuroinflammatory and neurodegenerative responses.
Parkinson's disease
Attenuation of the dopaminergic impairment in vivo; neuroprotection; improvement of psychiatric rating and reduction of agitation, nightmare
and aggressive behaviour in patients.
Multiple sclerosis
Improved signs of EAE in mice, antinflammatory and immunomodulatory
properties.
Huntington's
disease
Neuroprotective and antioxidant in mice transgenic models; no significant
clinically important differences in patients.
Hypoxia-ischemia
injury
Short term neuroprotective effects; inhibition of excitotoxicity, oxidative
stress and inflammation in vitro and in rodent models.
Pain
Analgesic effect in patients with neuropathic pain resistant to other
treatments.
Psychosis
Attenuation of the behavioural and glial changes in animal models of
schizophrenia; anti-psychotic properties on ketamine-induced symptoms
Anxiety
Reduction of muscular tension, restlessness, fatigue, problems in concentration, improvement of social interactions in rodent models of
anxiety and stress; reduced social anxiety in patients.
Depression
Anti-depressant effect in genetic rodent model of depression.
Cancer
Antiproliferative and anti-invasive actions in a large range of cancer types;
induction of autophagy-mediated cancer cell death; chemopreventive effects.
Nausea
Suppression of nausea and conditioned gaping in rats
Inflammatory
diseases
Antinflammatory properties in several in vitro and in vivo models;
inhibition of inflammatory cytokines and pathways.
Rheumatoid
arthritis
Inhibition of TNF-α in an animal model
Infection
Activity against methicillin-resistant Staphylococcus aureus
Inflammatory bowel and Crohn's
diseases
Inhibition of macrophage recruitment and TNF-α secretion in vivo and ex vivo; reduction in disease activity index in Crohn's patients.
Cardiovascular
diseases
Reduced infarct size through anti-oxidant and anti-inflammatory
properties in vitro and in vivo.
Diabetic
complications
Attenuation of fibrosis and myocardial dysfunction